Introduction: Recent reports have described the usefulness of carbon ion radiotherapy (CIRT) for inoperable sacral chordomas. However, its long-term local control rate needs to be improved. The present study identified the risk factors that affect the local relapse of sacral chordomas and the appropriate margins from the tumors. Methods: Forty-nine patients with sacral chordoma treated with CIRT between 2011 and 2022 were retrospectively analyzed. Factors predicting the risk of local recurrence were evaluated, including age, sex, tumor size, muscle invaded with tumor, and surgery before CIRT. To determine the appropriate margin, the distance between the clinical target volume (CTV) and the out-field recurrent lesions was analyzed. Results: The patients included 37 males and 12 females with a mean age of 67.1 years. A multivariate analysis showed that a tumor size >8 cm and invasion into the gluteus maximus muscle were significant risk factors with hazard ratios of 5.56 and 15.20 (p = 0.02 and 0.01), respectively. Out-field recurrence occurred in 13 cases, with 6, 3, and 4 relapses occurring in the muscle, bone, and both, respectively. The tumor occurred within 20 mm from the CTV in 60% of relapses in the muscles. Conclusion: The current study presented novel findings on CIRT for sacral chordomas, although there were several limitations, such as a short follow-up period to investigate slow-growth tumors and a small number of tumor specimens owing to inoperative cases. A tumor size >8 cm and invasion into the gluteus maximus muscle were shown to be risk factors for recurrence in the treatment of sacral chordoma with CIRT. Our findings further suggest that an additional 2-cm margin from the CTV in the muscle fiber direction is recommended during CIRT.

1.
Das
P
,
Soni
P
,
Jones
J
,
Habboub
G
,
Barnholtz-Sloan
JS
,
Recinos
PF
, et al
.
Descriptive epidemiology of chordomas in the United States
.
J Neuro Oncol
.
2020
;
148
(
1
):
173
8
.
2.
Pan
Y
,
Lu
L
,
Chen
J
,
Zhong
Y
,
Dai
Z
.
Analysis of prognostic factors for survival in patients with primary spinal chordoma using the SEER Registry from 1973 to 2014
.
J Orthop Surg Res
.
2018
;
13
(
1
):
76
.
3.
Kerekes
D
,
Goodwin
CR
,
Ahmed
AK
,
Verlaan
JJ
,
Bettegowda
C
,
Abu-Bonsrah
N
, et al
.
Local and distant recurrence in resected sacral chordomas: a systematic review and pooled cohort analysis
.
Glob Spine J
.
2019
;
9
(
2
):
191
201
.
4.
Imai
R
,
Kamada
T
,
Araki
N
;
Working Group for Bone and Soft Tissue Sarcomas
.
Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases
.
Int J Radiat Oncol Biol Phys
.
2016
;
95
(
1
):
322
7
.
5.
Demizu
Y
,
Imai
R
,
Kiyohara
H
,
Matsunobu
A
,
Okamoto
M
,
Okimoto
T
, et al
.
Carbon ion radiotherapy for sacral chordoma: a retrospective nationwide multicentre study in Japan
.
Radiother Oncol
.
2021
;
154
:
1
5
.
6.
Ruggieri
P
,
Angelini
A
,
Ussia
G
,
Montalti
M
,
Mercuri
M
.
Surgical margins and local control in resection of sacral chordomas
.
Clin Orthop Relat Res
.
2010
;
468
(
11
):
2939
47
.
7.
Angelini
A
,
Pala
E
,
Calabrò
T
,
Maraldi
M
,
Ruggieri
P
.
Prognostic factors in surgical resection of sacral chordoma
.
J Surg Oncol
.
2015
;
112
(
4
):
344
51
.
8.
Kayani
B
,
Hanna
SA
,
Sewell
MD
,
Saifuddin
A
,
Molloy
S
,
Briggs
TW
.
A review of the surgical management of sacral chordoma
.
Eur J Surg Oncol
.
2014
;
40
(
11
):
1412
20
.
9.
Fuchs
B
,
Dickey
ID
,
Yaszemski
MJ
,
Inwards
CY
,
Sim
FH
.
Operative management of sacral chordoma
.
J Bone Jt Surg Am
.
2005
;
87
(
10
):
2211
6
.
10.
Fujiwara
T
,
Tsuda
Y
,
Stevenson
J
,
Parry
M
,
Jeys
L
.
Sacral chordoma: do the width of surgical margin and the use of photon/proton radiotherapy affect local disease control
.
Int Orthop
.
2020
;
44
(
2
):
381
9
.
11.
Zuckerman
SL
,
Lee
SH
,
Chang
GJ
,
Walsh
GL
,
Mehran
RJ
,
Gokaslan
ZL
, et al
.
Outcomes of surgery for sacral chordoma and impact of complications: a report of 50 consecutive patients with long-term follow-up
.
Glob Spine J
.
2021
;
11
(
5
):
740
50
.
12.
Jeys
LM
,
Thorne
CJ
,
Parry
M
,
Gaston
CL
,
Sumathi
VP
,
Grimer
JR
.
A novel system for the surgical staging of primary high-grade osteosarcoma: the birmingham classification
.
Clin Orthop Relat Res
.
2017
;
475
(
3
):
842
50
.
13.
Radaelli
S
,
Fossati
P
,
Stacchiotti
S
,
Akiyama
T
,
Asencio
JM
,
Bandiera
S
, et al
.
The sacral chordoma margin
.
Eur J Surg Oncol
.
2020
;
46
(
8
):
1415
22
.
14.
Schneider
CA
,
Rasband
WS
,
Eliceiri
KW
.
NIH Image to ImageJ: 25 years of image analysis
.
Nat Methods
.
2012
;
9
(
7
):
671
5
.
15.
Bostel
T
,
Mattke
M
,
Nicolay
NH
,
Welzel
T
,
Wollschläger
D
,
Akbaba
S
, et al
.
High-dose carbon-ion based radiotherapy of primary and recurrent sacrococcygeal chordomas: long-term clinical results of a single particle therapy center
.
Radiat Oncol
.
2020
;
15
(
1
):
206
.
16.
Hanna
SA
,
Aston
WJ
,
Briggs
TW
,
Cannon
SR
,
Saifuddin
A
.
Sacral chordoma: can local recurrence after sacrectomy be predicted
.
Clin Orthop Relat Res
.
2008
;
466
(
9
):
2217
23
.
17.
Yonemoto
T
,
Tatezaki
S
,
Takenouchi
T
,
Ishii
T
,
Satoh
T
,
Moriya
H
.
The surgical management of sacrococcygeal chordoma
.
Cancer
.
1999
;
85
(
4
):
878
83
.
18.
Redmond
KJ
,
Schaub
SK
,
Lo
SFL
,
Khan
M
,
Lubelski
D
,
Bilsky
M
, et al
.
Radiotherapy for mobile spine and sacral chordoma: a critical review and practical guide from the spine tumor Academy
.
Cancers
.
2023
;
15
(
8
):
2359
.
19.
Akiyama
T
,
Ogura
K
,
Gokita
T
,
Tsukushi
S
,
Iwata
S
,
Nakamura
T
, et al
.
Analysis of the infiltrative features of chordoma: the relationship between micro-skip metastasis and postoperative outcomes
.
Ann Surg Oncol
.
2018
;
25
(
4
):
912
9
.
You do not currently have access to this content.